Gemcitabine/Capecitabine/ZD6474 in Advanced Solid Tumors

Completed · Phase 1

Conditions studied: Malignant Solid Tumour, Biliary Cancer, Pancreatic Cancer

In brief

Zactima will be used in this study to determine the highest dose that can be given safely as well as the side effects of Zactima when in combination with two FDA approved drugs; gemcitabine and capecitabine. This combination will be given to patients with advanced solid tumors. Once the highest dose of the combination has been determined, additional patients with biliary cancers (cholangiocarcinomas and gallbladder cancer) and locally advanced or metastatic pancreatic cancer will be treated at the highest determined dose for further studies.

Key facts

Study ID

NCT00551096

Run by

University of Colorado, Denver

People needed

23

Starts

2007-10-01

Expected to finish

2013-05-01

Last updated by the study team

2013-12-25

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age 18 years or older
• Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 (measure of your ability to perform everyday tasks)
• Life expectancy of at least three months
• Blood samples and other testing may apply for further testing of eligibility.

You may not qualify if…

• Uncontrolled illness (for example, current infections or heart conditions)
• Abnormal laboratory tests (such as blood or urine testing)
• Pregnant or breastfeeding women
• Further exclusion criteria may apply.

Where it is running

• University of Colorado Denver — Aurora, Colorado, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.